Sight Sciences Files 8-K on Executive Changes and Disclosures

TL;DR

Sight Sciences 8-K: Exec changes, exit costs, and Reg FD update.

AI Summary

Sight Sciences, Inc. filed an 8-K on August 27, 2025, reporting on cost-associated exit or disposal activities, departure of directors, election of directors, appointment of officers, and compensatory arrangements. The filing also includes a Regulation FD disclosure. The company is incorporated in Delaware and headquartered in Menlo Park, California.

Why It Matters

This 8-K filing indicates potential organizational changes and disclosures that could impact investor understanding of the company's leadership and strategic direction.

Risk Assessment

Risk Level: medium — Changes in directors or officers, along with exit costs, can signal underlying business challenges or strategic shifts that warrant investor attention.

Key Numbers

• 001-40587 — SEC File Number (Identifies the company's filing with the SEC.)
• 80-0625749 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Sight Sciences, Inc. (company) — Registrant
• August 27, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Menlo Park, California (location) — Principal Executive Offices
• 4040 Campbell Avenue Suite 100 (address) — Principal Executive Offices Address

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share SGHT The Nasdaq
• $2.7 million — h restructuring charge of approximately $2.7 million to $3.0 million primarily in the third
• $3.0 million — charge of approximately $2.7 million to $3.0 million primarily in the third quarter of 2025,
• $0.6 million — ock-based compensation of approximately $0.6 million to $1.0 million in the third quarter of
• $1.0 million — sation of approximately $0.6 million to $1.0 million in the third quarter of 2025. The Pla
• $72.0 million — or the year ending December 31, 2025 of $72.0 million to $76.0 million and reaffirms its expe
• $76.0 million — g December 31, 2025 of $72.0 million to $76.0 million and reaffirms its expectation for third
• $11.9 million — one will yield savings of approximately $11.9 million on an annualized basis. The Company i
• $95 — or the year ending December 31, 2025 to $95 to $99 million from $101 to $105 millio
• $99 million — year ending December 31, 2025 to $95 to $99 million from $101 to $105 million previously, t
• $101 — ber 31, 2025 to $95 to $99 million from $101 to $105 million previously, taking into
• $105 million — 2025 to $95 to $99 million from $101 to $105 million previously, taking into account the fac

Filing Documents

• sght-20250827.htm (8-K) — 54KB
• 0001531177-25-000007.txt ( ) — 169KB
• sght-20250827.xsd (EX-101.SCH) — 26KB
• sght-20250827_htm.xml (XML) — 5KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities On August 27, 2025, Sight Sciences, Inc. (the "Company") informed its employees that it is implementing a targeted plan, commencing immediately, intended to reduce operating expenses, improve cost efficiencies, and better align its operating structure for long-term, profitable growth (the "Plan"). The Plan is designed to optimize the Company's operating structure, help support the Company's cash position, drive enhanced focus on the Company's key strategic priorities, and maintain its path to breakeven without the need for any additional equity capital. Pursuant to the Plan, the Company intends to (a) reduce its headcount by 43 employees, or approximately 20% of its global workforce, and (b) reduce its operating expenses, principally by (i) delaying certain research and development project spend while prioritizing near term pipeline projects, (ii) reducing its selling, general, and administrative operating expenses by implementing measures to limit marketing, travel, and administrative costs, and (iii) not backfilling certain open and planned headcount. Approximately 45% of the impacted employees are in general and administrative functions, and the remaining impacted employees are split between employees in research and development and clinical functions and employees in sales and sales management functions. In addition, the Company is driving enhanced business unit focus by creating segment-specific leadership for both the Surgical Glaucoma and Dry Eye business segments and transitioning previously distributed business enablement functions to dedicated and focused resources for each business segment. As a result of implementing the Plan, the Company expects to record a cash restructuring charge of approximately $2.7 million to $3.0 million primarily in the third quarter of 2025, consisting mostly of one-time employee severance and benefits contribution costs. The Company also expects to record a non-

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure The Company reaffirms its prior revenue guidance for the year ending December 31, 2025 of $72.0 million to $76.0 million and reaffirms its expectation for third quarter 2025 surgical glaucoma revenue to be down by mid-single digits compared to the same period in the prior year. In addition, the Company estimates the workforce reductions associated with the Plan alone will yield savings of approximately $11.9 million on an annualized basis. The Company is updating its prior adjusted operating expenses guidance for the year ending December 31, 2025 to $95 to $99 million from $101 to $105 million previously, taking into account the factors discussed in this Current Report on Form 8-K (this "Current Report"). The Company plans to provide financial information reflecting adjustments to its financial results presented in accordance with the generally accepted accounting principles in the United States ("GAAP") for the third quarter and year ending December 31, 2025 to exclude the non-core operating costs discussed in this Current Report from its results of operations through the presentation of non-GAAP financial measures.* Cautionary Note Regarding Forward-Looking Statements This Current Report, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which statements are subject to considerable risks and uncertainties. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this Current Report that are not statements of his

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sight Sciences, Inc. Date: August 27, 2025 By: /s/ Alison Bauerlein Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR